MacroGenics, Inc. (MGNX)
MGNX Stock Price Chart
Explore MacroGenics, Inc. interactive price chart. Choose custom timeframes to analyze MGNX price movements and trends.
MGNX Company Profile
Discover essential business fundamentals and corporate details for MacroGenics, Inc. (MGNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Oct 2013
Employees
300.00
Website
http://www.macrogenics.comCEO
Eric Risser
Description
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MGNX Financial Timeline
Browse a chronological timeline of MacroGenics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is $0.03, while revenue estimate is $67.96m.
Earnings released on 13 May 2026
EPS came in at -$0.58 falling short of the estimated -$0.57 by -1.75%, while revenue for the quarter reached $20.78m , beating expectations by +36.30%.
Earnings released on 9 Mar 2026
EPS came in at -$0.22 surpassing the estimated -$0.42 by +47.62%, while revenue for the quarter reached $41.23m , beating expectations by +19.19%.
Earnings released on 12 Nov 2025
EPS came in at $0.27 surpassing the estimated -$0.48 by +156.25%, while revenue for the quarter reached $72.84m , beating expectations by +161.94%.
Earnings released on 14 Aug 2025
EPS came in at -$0.57 surpassing the estimated -$0.59 by +3.39%, while revenue for the quarter reached $22.24m , missing expectations by -8.89%.
Earnings released on 13 May 2025
EPS came in at -$0.65 falling short of the estimated -$0.61 by -6.56%, while revenue for the quarter reached $13.19m , beating expectations by +12.11%.
Earnings released on 20 Mar 2025
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%, while revenue for the quarter reached $17.73m , missing expectations by -48.12%.
Earnings released on 5 Nov 2024
EPS came in at $0.90 surpassing the estimated $0.21 by +328.57%, while revenue for the quarter reached $110.71m , beating expectations by +238.67%.
Earnings released on 7 Aug 2024
EPS came in at -$0.89 falling short of the estimated -$0.59 by -50.85%, while revenue for the quarter reached $10.80m , missing expectations by -48.43%.
Earnings released on 9 May 2024
EPS came in at -$0.84 falling short of the estimated -$0.67 by -25.37%, while revenue for the quarter reached $9.10m , missing expectations by -38.74%.
Earnings released on 7 Mar 2024
EPS came in at -$0.75 falling short of the estimated -$0.26 by -188.46%, while revenue for the quarter reached $10.72m , missing expectations by -67.15%.
Earnings released on 6 Nov 2023
EPS came in at -$0.52 falling short of the estimated -$0.11 by -392.89%, while revenue for the quarter reached $10.40m , missing expectations by -69.55%.
Earnings released on 9 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.52 by +30.77%, while revenue for the quarter reached $13.14m , missing expectations by -55.83%.
Earnings released on 9 May 2023
EPS came in at -$0.61 falling short of the estimated $1.07 by -157.01%, while revenue for the quarter reached $24.21m , missing expectations by -74.33%.
Earnings released on 15 Mar 2023
EPS came in at $0.21 surpassing the estimated $0.10 by +110.00%, while revenue for the quarter reached $71.18m , beating expectations by +21.09%.
Earnings released on 3 Nov 2022
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $41.73m , beating expectations by +42.52%.
Earnings released on 8 Aug 2022
EPS came in at -$0.67 surpassing the estimated -$0.97 by +30.93%, while revenue for the quarter reached $26.01m , beating expectations by +83.64%.
Earnings released on 3 May 2022
EPS came in at -$1.08 falling short of the estimated -$0.84 by -28.57%, while revenue for the quarter reached $10.67m , beating expectations by +34.38%.
Earnings released on 24 Feb 2022
EPS came in at -$0.95 falling short of the estimated -$0.83 by -14.46%, while revenue for the quarter reached $13.62m , missing expectations by -38.71%.
Earnings released on 2 Nov 2021
EPS came in at -$0.86 falling short of the estimated -$0.63 by -36.51%, while revenue for the quarter reached $15.58m , missing expectations by -58.15%.
Earnings released on 29 Jul 2021
EPS came in at -$0.66 falling short of the estimated -$0.28 by -135.71%, while revenue for the quarter reached $30.37m , beating expectations by +13.13%.
MGNX Stock Performance
Access detailed MGNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
